The Centers for Medicare & Medicaid Services has finalized a rule that will expand Medicare coverage to include continuous sugar monitoring (CGM) devices that aren’t approved for treatment decisions.
Proposed in November 2020 The final CMS rule is applicable to CGMs that integrate with Medtronic insulin pumps. These CGMs have not been approved by the US Food and Drug Administration to replace the need for blood glucose measurement using fingersticks in determining insulin or other medication that reduces glucose.
Other CGM systems, Dexcom G6 and Abbott Libre, have “therapeutic” indications and are covered under Medicare, as was the combined insulin pump-CGM Tandem Diabetes Care Control-IQ technology system.
The expanded coverage means that patients using the Medtronic 770G or 630G hybrid closed loop insulin delivery systems will receive coverage for all the systems’ components, and that patients who are aging into Medicare won’t lose insurance coverage for those devices.
Medtronic will continue to offer its CGM Access Discount to all Medicare customers until the ruling becomes effective. The rule was approved on December 21, 2021 and will take effect 60 days after official publication.
Miriam E. Tucker is freelance journalist from the Washington, DC, area. She is a regular contributor for Medscape. Other work appears in the Washington Post, NPR’s Shots blog and Diabetes Forecast magazine. She’s on Twitter @MiriamETucker.
Follow Medscape on Facebook, Twitter and Instagram for more information.
Content Source: https://www.medscape.com/viewarticle/965693?src=rss